Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Auspex Pharmaceuticals, Inc.

Home Clinical Trial Sponsors and OrganizationsAuspex Pharmaceuticals, Inc.

Auspex Pharmaceuticals, Inc.

ACTIVE

3333 N Torrey Pines Ct Ste 400, 加利福尼亚州圣迭戈县, California, United Stateswww.auspexpharma.comSubsidiary35 employeesEstablished: 2001-01-01

Part of Teva Pharmaceutical Industries Ltd.

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

Clinical Trials

17

12 active

Approvals

0

Total approvals

Agencies

0

Regulatory bodies

Founded

2001

Overview

Trial Phase Distribution

Phase

Trials

Share

Phase 1

11

64.7%

Phase 3

3

17.6%

Phase 2

1

5.9%

Trial Status Distribution

Active, not recruiting

12

70.6%

Completed

5

29.4%

Clinical Trials

Trials sponsored by this organization (17)

A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, FIXED-DOSE STUDY OF SD-809 (DEUTETRABENAZINE) FOR THE TREATMENT OF MODERATE TO SEVERE TARDIVE DYSKINESIA

Active, not recruiting

Feb 2015288 participants

A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, FIXED-DOSE STUDY OF SD-809 (DEUTETRABENAZINE) FOR THE TREATMENT OF MODERATE TO SEVERE TARDIVE DYSKINESIA

Active, not recruiting

Jan 2015200 participants

AN OPEN-LABEL, LONG-TERM SAFETY STUDY OF SD-809 (DEUTETRABENAZINE) FOR THE TREATMENT OF MODERATE TO SEVERE TARDIVE DYSKINESIA

Active, not recruiting

Jan 2015337 participants

A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, FIXED-DOSE STUDY OF SD-809 (DEUTETRABENAZINE) FOR THE TREATMENT OF MODERATE TO SEVERE TARDIVE DYSKINESIA

Active, not recruiting

Nov 2014288 participants

A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, FIXED-DOSE STUDY OF SD-809 (DEUTETRABENAZINE) FOR THE TREATMENT OF MODERATE TO SEVERE TARDIVE DYSKINESIA

Active, not recruiting

Nov 2014288 participants

A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, FIXED-DOSE STUDY OF SD-809 (DEUTETRABENAZINE) FOR THE TREATMENT OF MODERATE TO SEVERE TARDIVE DYSKINESIA

Active, not recruiting

Nov 2014288 participants

Addressing Involuntary Movements in Tardive Dyskinesia

Oct 2014298 participants

Reducing Involuntary Movements in Participants With Tardive Dyskinesia

Oct 2014343 participants

Page 1 of 3

Approvals

No approval data available

News

No news articles found

On this page

Overview
Clinical Trials17
Approvals
News

Back to Organizations